Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $2.48 Million - $3.24 Million
62,600 Added 21.88%
348,700 $18 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $181,125 - $238,455
-4,500 Reduced 1.55%
286,100 $11.9 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $3.77 Million - $4.27 Million
-78,500 Reduced 21.27%
290,600 $15.8 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $15.2 Million - $18.1 Million
313,300 Added 561.47%
369,100 $18.9 Million
Q3 2023

Nov 15, 2023

SELL
$57.89 - $64.73 $1.76 Million - $1.97 Million
-30,400 Reduced 35.27%
55,800 $3.24 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $5.49 Million - $6.1 Million
86,200 New
86,200 $5.51 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $5,070 - $3 Million
-39,000 Reduced 88.24%
5,200 $369,000
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $2.04 Million - $2.25 Million
28,100 Added 174.53%
44,200 $3.4 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $547,172 - $656,108
8,900 Added 123.61%
16,100 $1.18 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $359,321 - $418,884
-6,700 Reduced 48.2%
7,200 $448,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $822,463 - $963,409
13,900 New
13,900 $824,000
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $4.18 Million - $6.07 Million
-90,000 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $5.91 Million - $7.7 Million
-120,000 Reduced 57.14%
90,000 $5.78 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $8.55 Million - $10.1 Million
-200,000 Reduced 48.78%
210,000 $10.6 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $18.5 Million - $22.1 Million
410,000 New
410,000 $19.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.